Open to women nationwide living with ovarian cancer. The program is free but pre-registration is required. Those who cannot access the webinar can participate via toll-free teleconference. To learn more or to register, call Support Connection at 914-962-6402 or 800-532-4290.

Topics will include: The newest information on the development of drugs for advanced ovarian cancer; the most current FDA approvals for ovarian cancer; Information presented at the most recent national conferences. There will also be a Q & A period. 

SPEAKER: Douglas A. Levine, M.D., NYU Langone Perlmutter Cancer Center: In addition to his clinical practice, Dr. Levine is the Head of the Gynecology Research Laboratory, where he studies cancer prevention, precision medicine, and rare tumors with unmet needs. He serves as the translational scientist on many national clinical trials determining what genomic alterations are associated with response to targeted therapies. He discovered universal mutations in SMARCA4that drive small cell carcinoma of the ovary, hypercalcemic type. Dr. Levine has an outstanding level of expertise and leadership in ovarian and endometrial cancer research and a deep commitment to women’s health.